Strongbridge Biopharma plc (SBBP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Strongbridge Biopharma plc (SBBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013208
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Strongbridge Biopharma plc (Strongbridge), formerly Cortendo plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, a genetic neuromuscular disorder. Strongbridge acquired the US rights to KEVEYIS (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. KEVEYIS holds orphan drug designation in the US. Its pipeline products include COR-003 (levoketoconazole), a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome; and COR-005, a novel somatostatin analog for the treatment of acromegaly, with potential use in Cushing’s syndrome and neuroendocrine tumors. Strongbridge’s primary focus is on building franchise around rare endocrine disorders including product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly. Strongbridge is headquartered in Trevose, Pennsylvania, the US.

Strongbridge Biopharma plc (SBBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Strongbridge Biopharma plc, Medical Devices Deals, 2011 to YTD 2017 10
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Strongbridge Biopharma Acquires US rights to Keveyis from Taro Pharma 13
Strongbridge Biopharma Acquires Somatoprim from Aspireo Pharma 15
Licensing Agreements 16
Cortendo Enters into Licensing Agreement with Antisense Therapeutics 16
Equity Offering 18
Strongbridge Biopharma Raises USD25 Million in Public Offering of Shares 18
Strongbridge Biopharma Raises USD3 Million in Private Placement of Shares 20
Strongbridge Biopharma to Raise USD40 Million in Public Offering of Shares 21
Strongbridge Biopharma Plans to Raise Funds through Private Placement of Shares 22
Strongbridge Biopharma Raises USD35 Million in Private Placement of Shares and Warrants 23
Strongbridge Biopharma Raises USD25 Million in IPO 25
Cortendo Raises USD33.2 Million in Private Placement of Shares 27
Cortendo to Raise USD33.2 Million in Private Placement of Shares 28
Strongbridge Biopharma Raises USD26.4 Million in Private Placement of Shares 30
Cortendo Raises USD37.5 Million in Private Placement of Shares 31
Cortendo Raises USD11 Million in Private Placement of Shares 33
Cortendo Raises USD12.6 Million in Private Placement of Shares 34
Cortendo Raises USD2.1 Million in Private Placement of Shares 35
Cortendo Raises USD0.7 Million in Private Placement of Shares 36
Cortendo Raises USD3.1 Million in Private Placement of Shares 37
Strongbridge Biopharma plc – Key Competitors 38
Strongbridge Biopharma plc – Key Employees 39
Strongbridge Biopharma plc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Nov 14, 2017: Strongbridge Biopharma Provides Corporate Update and Reports Third Quarter 2017 Financial Results 41
Aug 07, 2017: Strongbridge Biopharma Provides Updates on KEVEYIS Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results 44
May 16, 2017: Strongbridge Biopharma Provides Corporate Update and Reports First Quarter 2017 Financial Results 47
Mar 27, 2017: Strongbridge Biopharma Provides Corporate Update and Reports Full-Year 2016 Financial Results 49
Dec 23, 2016: Strongbridge Biopharma Provides Corporate and Financial Update 51
May 17, 2016: Strongbridge Biopharma Reports First Quarter 2016 Financial Results 54
Mar 24, 2016: Strongbridge Biopharma Reports Full-Year 2015 Financial Results 55
Corporate Communications 56
Oct 03, 2016: Strongbridge Biopharma Announces Appointment of Jeffrey W. Sherman, M.D., FACP, to Board of Directors 56
Product News 57
05/31/2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the European Congress of Endocrinology 57
Clinical Trials 58
May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology 58
Apr 04, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference 59
Other Significant Developments 60
Sep 25, 2017: Strongbridge Biopharma Launches the Uncovering Periodic Paralysis Genetic Testing Program 60
Mar 07, 2016: Strongbridge Biopharma Provides Update on Corporate Progress 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Key Facts 2
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Strongbridge Biopharma plc, Deals By Therapy Area, 2011 to YTD 2017 9
Strongbridge Biopharma plc, Medical Devices Deals, 2011 to YTD 2017 10
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Strongbridge Biopharma Acquires US rights to Keveyis from Taro Pharma 13
Strongbridge Biopharma Acquires Somatoprim from Aspireo Pharma 15
Cortendo Enters into Licensing Agreement with Antisense Therapeutics 16
Strongbridge Biopharma Raises USD25 Million in Public Offering of Shares 18
Strongbridge Biopharma Raises USD3 Million in Private Placement of Shares 20
Strongbridge Biopharma to Raise USD40 Million in Public Offering of Shares 21
Strongbridge Biopharma Plans to Raise Funds through Private Placement of Shares 22
Strongbridge Biopharma Raises USD35 Million in Private Placement of Shares and Warrants 23
Strongbridge Biopharma Raises USD25 Million in IPO 25
Cortendo Raises USD33.2 Million in Private Placement of Shares 27
Cortendo to Raise USD33.2 Million in Private Placement of Shares 28
Strongbridge Biopharma Raises USD26.4 Million in Private Placement of Shares 30
Cortendo Raises USD37.5 Million in Private Placement of Shares 31
Cortendo Raises USD11 Million in Private Placement of Shares 33
Cortendo Raises USD12.6 Million in Private Placement of Shares 34
Cortendo Raises USD2.1 Million in Private Placement of Shares 35
Cortendo Raises USD0.7 Million in Private Placement of Shares 36
Cortendo Raises USD3.1 Million in Private Placement of Shares 37
Strongbridge Biopharma plc, Key Competitors 38
Strongbridge Biopharma plc, Key Employees 39
Strongbridge Biopharma plc, Subsidiaries 40

★海外企業調査レポート[Strongbridge Biopharma plc (SBBP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Medimetriks Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Medimetriks Pharmaceuticals Inc (MPI) is a specialty pharmaceutical company that offers skincare products. The company provides personal care products such as cleansers, nutritional supplements, cosmetic creams, topical suspension, ointment, topical solution, and moisturizer. It offers produ …
  • HollyFrontier Corp (HFC):企業の財務・戦略的SWOT分析
    HollyFrontier Corp (HFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CNX Resources Corp (CNX):石油・ガス:M&Aディール及び事業提携情報
    Summary CNX Resources Corporation (CNX Resources), formerly CONSOL Energy Inc., is an independent oil and natural gas company. It carries out the exploration, development, production, gathering, processing and acquisition of natural gas properties in the Appalachian Basin. The company has interests …
  • Nationwide Building Society:企業のM&A・事業提携・投資動向
    Nationwide Building Society - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nationwide Building Society Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Bayerische Motoren Werke AG (BMW):企業の財務・戦略的SWOT分析
    Bayerische Motoren Werke AG (BMW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Tiger Brands Ltd (TBS):企業の財務・戦略的SWOT分析
    Tiger Brands Ltd (TBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Indianapolis Power & Light Co:電力:M&Aディール及び事業提携情報
    Summary Indianapolis Power & Light Co (IPL), a subsidiary of IPALCO Enterprises Inc, is an integrated electric utility. The company generates, transmits, distributes, and sells electric energy. It produces electricity from coal, oil, and natural gas sources. IPL owns and operates power plants in Ind …
  • UMN Pharma Inc (4585):企業の財務・戦略的SWOT分析
    Summary UMN Pharma Inc (UMN Pharma) is a biopharmaceutical company that manufactures therapeutic for muscular dystrophy, diabetes and influenza. The company’s products include UMN-0501, UMN-0502, UMN-2003, UMN-0901 and UMN-2002, among others. Its UMN-0502 is a seasonal influenza vaccine. UMN Pharma’ …
  • Acorda Therapeutics Inc (ACOR)-製薬・医療分野:企業M&A・提携分析
    Summary Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. The company’s commercial products include Ampyra (dalfampridine), a treatment to improve walking in patients with multiple …
  • Boehringer Ingelheim GmbH-医療機器分野:企業M&A・提携分析
    Summary Boehringer Ingelheim GmbH (Boehringer), a subsidiary of C. H. Boehringer Sohn AG & Co KG is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer healt …
  • Gulf Resources, Inc. (GURE):企業の財務・戦略的SWOT分析
    Gulf Resources, Inc. (GURE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Little Caesar Enterprises Inc:企業の戦略・SWOT・財務情報
    Little Caesar Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Little Caesar Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Implanet SA (IMPL):企業の財務・戦略的SWOT分析
    Summary Implanet SA (Implanet) is a medical device company that designs, manufactures and markets orthopaedic products. The company offers spine, knee and arthroscopy products. Its spine products are used for the treatment of spinal disorders and spinal fusion surgery. Implanet offers resorbable anc …
  • Promimic AB-医療機器分野:企業M&A・提携分析
    Summary Promimic AB (Promimic) is a biomaterial company that develops and markets implant surface modifications and synthetic bones. The company’s products comprise metals, ceramics, polymers, porous materials and pyrocarbon. Its HA-nano surface is a coating based on nanocrystalline hydroxyapatite p …
  • Comet Ridge Ltd (COI):企業の財務・戦略的SWOT分析
    Summary Comet Ridge Ltd (CRL) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company holds interests in Mahalo project located in the Denison trough area of Queensland's Bowen Basin near Rolleston. It also holds interest in PEL 6 …
  • Intercontinental Hotels Group Plc:企業の戦略・SWOT・財務分析
    Intercontinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report Summary Intercontinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • NextEra Energy Inc (NEE)-エネルギー分野:企業M&A・提携分析
    Summary NextEra Energy, Inc. (NEE), formerly FPL Group, Inc., is an energy company that generates, transmits and distributes electricity together with its subsidiaries. The company generates power through various sources such as nuclear, coal, oil and natural gas-fired facilities, and hydro power pl …
  • MemorialCare Health System-製薬・医療分野:企業M&A・提携分析
    Summary MemorialCare Health System (MemorialCare) is a nonprofit health system that offers medical services. The center offers care services such as stroke care, cancer care, rehabilitation and physical therapy, weight-loss surgery, heart and vascular care, breast care, imaging and radiology, labora …
  • TOTAL S.A.:企業の戦略・SWOT・財務情報
    TOTAL S.A. - Strategy, SWOT and Corporate Finance Report Summary TOTAL S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Briscoe Group Ltd (BGP):企業の財務・戦略的SWOT分析
    Briscoe Group Ltd (BGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆